SCHEMBL6503175

SCHEMBL6503175

Cc1nc2ccc(C(=O)O)nc2n1Cc1ccc(N(C)C(=O)OCc2ccccc2)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
ALDH1A1 P00352 3/20 0.38
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 2/20 0.37
HPGD P15428 2/20 0.37
HTT P42858 2/20 0.37
HSD17B10 Q99714 2/20 0.37
PTGDR2 Q9Y5Y4 1/20 0.36
PTGER1 P34995 1/20 0.35
PPARG P37231 2/20 0.34
GLP1R P43220 2/20 0.34
MEN1 O00255 2/20 0.33
GAA P10253 1/20 0.33
DHODH Q02127 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6494455 0.93 KMT2A (0.39) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6491707 0.90 ALDH1A1 (0.40) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6503105 0.85 ALDH1A1 (0.38) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6299347 0.85 ALDH1A1 (0.42) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6490570 0.85 PPARG (0.51) ALDH1A1MAPTSMN1; SMN2KDM4EHPGD
SCHEMBL6305870 0.84 ALDH1A1 (0.41) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6307227 0.83 KMT2A (0.42) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6300435 0.82 S1PR1 (0.50) KMT2AALDH1A1MAPTSMN1; SMN2MEN1
SCHEMBL6491577 0.82 ALDH1A1 (0.39) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL6300239 0.81 ALDH1A1 (0.41) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A KMT2A 1625/4885ALDH1A1 476/4885MAPT 4144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.